CAMMA-2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 90 patients (estimated)
- Sponsors
- Hoffmann-La Roche
- Tags
- Bispecific Antibody, CD3, FCRH5
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1308
- NCT Identifier
- NCT05535244
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.